Drug reference

Teneligliptin

Dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) · Antidiabetic

Also known as Teneligliptin hydrobromide hydrate

START

20 mg OD (fixed dose, no titration); can be taken with or without food; check baseline renal function and LFTs

TYPICAL MAX

20 mg OD (no dose escalation needed)

STOP IF

Signs of pancreatitis (severe abdominal pain, vomiting), severe joint pain, anaphylaxis

WATCH

HbA1c at 3-monthly intervals, signs of pancreatitis, renal function annually

CDSCO approvedSchedule HJan AushadhiNPPA price-controlledATC A10BH08

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 20min · absorption onset
PEAK: 1.3h · Peak plasma concentration
t½: 1.2d · Long half-life (26-30 hours)
DURATION: 1d · 24-hour coverage with once-daily dosing

EXCRETION

Fecal (~70%, mostly unchanged)

route + CYP

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid in pregnancy; limited human data

FDA category + note

Available in India

331 branded formulations and 6 fixed-dose combinations. Look up specific brands in the Drugs workspace.

Jan Aushadhi — generic available at GoI pharmacies

Mechanism

Potent, selective, and long-acting DPP-4 inhibitor that prolongs the half-life of endogenous incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin secretion and suppressing glucagon release. Unique 'anchor-lock-domain' structure provides strong enzyme binding and slow dissociation.

Indications

Type 2 diabetes mellitus (monotherapy or in combination with metformin, sulfonylureas, or insulin)

Dosing

Adult: 20 mg once daily (fixed dose, no titration needed)
Pediatric: Not recommended under 18 years
Renal adjustment: No dose adjustment required even in severe renal impairment (primarily biliary/fecal excretion)
Hepatic adjustment: No dose adjustment needed in mild-moderate hepatic impairment; limited data in severe
Geriatric: No dose adjustment based on age
Max dose: 20 mg/day